Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 14/20 | 0.67 |
| ▸ | DRD3 | P35462 | 13/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922758 | 0.89 | RAB9A (0.64) | RAB9ADRD2DRD3HDAC1PKM | |
| SCHEMBL6220801 | 0.85 | DRD2 (0.68) | RAB9ADRD2DRD3KCNH2 | |
| SCHEMBL6226262 | 0.83 | DRD2 (0.65) | RAB9ADRD2DRD3HDAC1KCNH2 | |
| SCHEMBL6219605 | 0.83 | HDAC1 (0.57) | RAB9ADRD2DRD3HDAC1KCNH2 | |
| SCHEMBL8151399 | 0.80 | DRD2 (0.62) | RAB9ADRD2DRD3HDAC1PKM | |
| SCHEMBL6223445 | 0.80 | PRMT5 (0.48) | RAB9ADRD2DRD3KCNH2 | |
| SCHEMBL6220245 | 0.80 | HDAC1 (0.56) | RAB9ADRD2DRD3HDAC1PKM | |
| SCHEMBL18937416 | 0.80 | RAB9A (0.69) | RAB9ADRD2DRD3HDAC1PKM | |
| SCHEMBL6224468 | 0.79 | DRD2 (0.47) | RAB9ADRD2DRD3KCNH2 | |
| SCHEMBL2198557 | 0.78 | DRD2 (0.59) | RAB9ADRD2DRD3HDAC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6903103-B2 | Linear cyclic ureas | LES LABORATORIES SERVIER (FR) | 2005-06-07 | — | — | US | disclosed |
| EP-1113014-B1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | RAB9A 1919/4885DRD2 3536/4885DRD3 2304/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | RAB9A 2287/4885DRD2 3284/4885DRD3 2124/4885 |
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | RAB9A 2287/4885DRD2 3284/4885DRD3 2124/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | RAB9A 2287/4885DRD2 3284/4885DRD3 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.